IFIB 2026

1 – 2 Oct 2026 | Roma, Italy

ICHNOVIA

Startup

www.ichnovia.com/Roma, Italy
1 profile visit

About

ICHNOVIA is a biotech company developing a new approach to the early detection of pancreatic cancer (PDAC), one of the cancers with the greatest unmet need for earlier diagnosis.

Our technology combines nanoparticles, protein-corona profiling and artificial intelligence to capture and interpret a disease-associated protein fingerprint directly from blood.

Rather than looking for a single biomarker, our approach analyses the complex biological signature generated by the interaction between nanoparticles and plasma proteins. AI is then used to identify patterns associated with pancreatic cancer.

Our goal is to make early detection accessible and scalable for at-risk populations, starting with people over 50 with new-onset diabetes, a population of particular interest for PDAC risk stratification.

ICHNOVIA is currently at TRL 4, with the technology tested on human blood samples. Our next major milestone is to advance clinical validation, analytical robustness and repeatability, while progressing the regulatory pathway toward an IVD solution for clinical use.

The project originates from academic research and is being developed through an ecosystem connecting scientists, clinicians, universities, hospitals, industry and business. ICHNOVIA holds worldwide licensing rights to its underlying patented technology, with IP protection already granted in key European jurisdictions and additional international patent applications pending.

We are now opening a €3 million Seed investment round to fund clinical validation, further analytical development, regulatory activities and the transition from research toward clinical application.

At IFIB 2026, we are particularly interested in meeting life-science investors, diagnostic and MedTech companies, pharmaceutical groups, clinical partners and strategic industrial partners interested in pancreatic cancer, early detection, precision medicine and next-generation diagnostics.

Our ambition is simple: change the history of pancreatic cancer by making earlier detection possible for the people who need it most.

Social media

Areas of activity

BIOLOGY and BIOTECHNOLOGY

Biochemistry / BiophysicsIn vitro Testing, Trials

GENOME RESEARCH

BioinformaticsGene Expression, Proteome Research

MICRO AND NANO TECHNOLOGY

Micro & Nanotechnology related to Biological Sciences

SUPPLY CHAIN

Design / R&DTesting & Analytics

Representatives

CEO

ICHNOVIA

Marketplace (1)

  • Partnership

    Next clinical validation

    Concluded out roadshow and out first seed round, we'll start - supporter by Deloitte - clinical validation, ponentially multicentric. we are open to examine pontential partnership.

    Author

    CEO at ICHNOVIA

    Milano, Italy